Biotech stocks

Shareholders in AstraZeneca have rebelled over proposals to raise bonus levels for its bosses.

Merck, the biopharma giant, dominates the biggest disease sector and looks reasonably valued, says Dr Mike Tubbs.

Elliott, s US hedge fund, took an undisclosed multibillion-pound stake in GSK last week, driving the share price up by 4.6%.

Healthcare is set for strong long-term expansion but looks cheap. That makes this investment trust worth buying, says Max King.

A decade ago, Stéphane Bancel took a gamble and joined a fledgling start-up working on an unproven new technology. The gamble paid off with the rise o…

Grabbing and hoarding vaccine supplies, or even manufacturing one’s own, might seem to make sense for a state in an emergency. But the damage done to …

AstraZeneca’s boss Pascal Soriot was winning plaudits for his stewardship when the Covid-19 pandemic struck. Since then, he’s been having a hard time …

Companies delivering scientific instruments – products to measure and analyse our world – are crucial to sectors ranging from telecommunications to ph…

Professional investor Marek Poszepcynski of the International Biotechnology Trust picks three biotech stocks with good pipelines, strong management te…

Several European countries have suspended their use of AstraZeneca's Covid vaccine – for no good scientific reason. Matthew Partridge reports.

Johnson & Johnson’s vaccine has been approved in the US, a sign that the world is making solid progress against Covid-19. Matthew Partridge reports

Traditionally dismissed as a relative backwater, this branch of medicine is about to move into the limelight thanks to ageing populations and major br…

The extraordinarily rapid development of effective treatments against the coronavirus is a triumph of biotechnology, says Dr Mike Tubbs. He reviews th…

AstraZeneca and Pfizer are being attacked by the EU over what it claims are delays in delivering the Covid vaccine.

AstraZeneca, the British pharma giant, was almost swallowed up by Pfizer a few years ago. Now it has struck a megadeal of its own. Matthew Partridge r…

Governments and companies can learn from the extraordinary global effort to create a vaccine to defeat Covid-19, says Matthew Lynn.

The news of Covid vaccines has delighted many. But not Argonaut Capital's Barry Norris. He tells Merryn why vaccines aren't the panacea people think t…

Calls to restrain drug companies' profits from making Covid-19 vaccines are misplaced and would do more harm than good, says Matthew Lynn

Another week, another Covid-19 vaccine. This one from AstraZeneca and Oxford University is homegrown and ready to roll out fast. Matthew Partridge rep…

Ugur Sahin and Özlem Türeci are an unassuming Turkish-German couple who had already made their fortune as biotech entrepreneurs when a strange new vi…

America’s Moderna has come up with a vaccine even more promising than last week’s offering from Pfizer and BioNTech. Matthew Partridge reports

As the vaccine news has shown, you don't have to think too far outside of the box to get ahead of the herd, says John Stepek.

A vaccine that appears so far to be safe and effective is making its way through the final trials before commercialisation. There are reasons to be ch…

Novo Nordisk leads the global market in diabetes treatments and looks a solid long-term buy, says Dr Mike Tubbs.